What is Allevi?
Allevi is recognized for its contributions to the field of 3D bioprinting, providing researchers with advanced bioprinters and bioinks essential for tissue engineering, organ-on-a-chip applications, and pharmaceutical research. Their product line, including the Allevi 1, 2, and 3 bioprinters, is designed for precision and versatility, enabling the printing of diverse cell lines and biomaterials. These solutions are instrumental in accelerating drug discovery, regenerative medicine, and disease modeling. Although Allevi ceased bioprinter production in 2023, they continue to support the bioprinting community through software and material provisions, positioning themselves as a key enabler of cutting-edge biological research.
How much funding has Allevi raised?
Allevi has raised a total of $397K across 2 funding rounds:
Debt
$150K
Debt
$247K
Debt (2020): $150K with participation from PPP
Debt (2021): $247K led by PPP
Key Investors in Allevi
PPP
Public-Private Partnership
PPP
Public-Private Partnership
Undisclosed investor
Undisclosed investor participating in the funding round, contributing to the company's overall capital structure.
What's next for Allevi?
The recent strategic investment, alongside the company's substantial total funding, suggests a focus on sustaining its role in the bioprinting ecosystem, potentially through software development, material innovation, or strategic partnerships. Given the 'large-scale late-stage funding' context, Allevi is likely leveraging this capital to solidify its market position and continue supporting advanced research applications. The company's trajectory indicates a commitment to enabling breakthroughs in regenerative medicine and pharmaceutical development, even as its hardware manufacturing model evolves.
See full Allevi company page
